Research progress of plasminogen in the treatment of congenital plasminogen deficiency
Congenital plasminogen deficiency(C-PLGD),also referred to as type Ⅰ plasminogen deficiency,plasminogen deficiency or hypoplasminogenemia,is an ultra-rare autosomal recessive disorder of the fibrinolytic system,which is mainly manifested by the abnormal extravascular accumulation and growth of fibrin-rich,ligneous pseudomembranous lesions on mucous membranes throughout the body.Left untreated,these lesions may impair normal tissue and organ function,and impact patients'quality of life.Currently,there is no specific replacement therapy approved for the treatment of C-PLGD in China.As such,treatment options have been limited to non-specific therapies and interventions,including surgery,all of which have been proved to be less effective.Foreign clinical trials have shown that replacement therapy with human glutamate-plasminogen can consistently increase plasminogen activity and improve the clinical symptoms of C-PLGD patients,and it is well tolerated.This article provided an overview of the research progress on the treatment of C-PLGD with human plasminogen,in order to provide some ideas and basis for its clinical application and research in the treatment of plasminogen deficiency.
NETL
NSTL
万方数据
